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Statin autoimmune necrotizing myopathy diagnosed
after a motor vehicle accident
Julia Poe, BA1, Dominika Lozowska, MD1, Stacy Dixon, MD2

ABSTRACT
One of the most commonly prescribed lipid lowering medications are statins. In the
majority of cases, statins are generally well tolerated. In rare instances, statin induced
necrotizing autoimmune myositis (SINAM) can occur. The following case presents a
patient with a fifteen-year history of simvastatin use who developed SINAM following a
motor vehicle accident.
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A 71-year-old white male with a history of
hypertension and hyperlipidemia (treated with
simvastatin for fifteen years) was seen in the
electromyography (EMG) lab to work up severe
muscle weakness which he reported began three
days after an MVA that occurred three months prior.
He also complained of fatigue, but denied dysphagia,
rashes, pigmenturia, delayed motor milestones when
growing up, or family history of neuromuscular
disease. The emergency room evaluation after his
MVA focused on a hypertensive crisis and chest pain,
but cardiac workup was negative and the patient was
discharged. Physical examination prior to the EMG
showed symmetric proximal weakness in both upper
and lower extremities with neck and distal muscle
strength preserved. Power was 4/5 in bilateral biceps
brachii and triceps brachii, 3/5 in deltoids, 4-/5 in
pectoralis, 3/5 in infraspinatus, and 3/5 in hip flexors.
Reflexes were 1+ throughout with absent patellar
and achilles reflexes. In all four extremities, sensation
remained intact and there was no tenderness to
palpation. We were unable to assess the patient’s gait
due to the extent of weakness.
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EMG of the right arm and leg showed an acute
on chronic myopathic process with evidence of
irritability of muscle membranes (abundant waning
discharges) and diffuse fibrillations including in the L4
and C7 paraspinal muscles. Creatinine phospokinase
(CPK) was 11,353, LDH 997, AST 405, ALT 512, ESR
27, GGT 130. At this time, a decision to discontinue
the patient’s statin was made. Jo1 antibody, urine
myoglobin, hemoglobin A1c, and myositis panel
were negative. Limb girdle muscular dystrophy
genetic panel was negative. MRI of the cervical and
lumbar spine showed diffuse degenerative changes,
but no abnormal cord signal. MRI of the left femur
showed diffuse, abnormal, increased STIR signal and
mild fatty atrophy of the thigh musculature that was
most prominent in the anterior aspect (Figure 1).
Light microscopy of the left deltoid and quadriceps
muscle showed acute myopathy (Figure 2). Trichrome
and H&E stains showed mild variation in fiber size.
Moderately increased internal nuclei were seen.
ATPase stains showed atrophy of both fiber types.
Acid phosphatase stain showed macrophage activity
in necrotic fibers and connective tissues.
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FIGURE 1. MRI with and without of the left femur.
A) T1 sequence showing mixed age edema, fatty replacement and atrophy in anterior hamstrings.
B) FatSat sequence showing soft tissue fluid and edema with increased heterogeneity.

FIGURE 2. Histochemistry of left quadriceps and deltoid muscle biopsy. Modified Trichrome, Verhoeff Van Gieson, and
H&E stains revealed mild variation in fiber size.
Moderately increased internal nuclei, moderate degenerating, basophilic, and necrotic fibers were seen, some round (red
arrow).
ATPase series (pH 9.4 and 4.6) revealed variation in fiber size due to atrophy in both fiber types. Non-specific esterase and
acid phosphatase reactions reveal macrophages actively in necrotic fibers and connective tissue (blue arrow).
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Given the EMG and imaging findings and high
suspicion for statin induced necrotizing autoimmune
myopathy (SINAM), an anti-HMG CoA reductase
antibody (HMGCR ab) was sent which was high (>200
units). He was started on empiric corticosteroids
(prednisone 1mg/kg). He showed improvement in
symptoms over the next several days. One month
later he could ambulate with a walker, and later
strength returned to baseline. Due to adverse steroid
effects prednisone was stopped and patient was
started on weekly methotrexate 7.5mg with folic acid,
which he has tolerated well for over 2 years.
Consent was obtained from the patient.
DISCUSSION
Statin therapy is commonly prescribed for
hyperlipidemia. In 2005, reports estimated that 29.7
million people were taking statins.4 Approximately
20% of patients taking statins will develop myalgias.5
Myotoxicity is usually self-limited, resolving after
stopping the offending drug or switching from
atorvastatin or simvastatin to another statin, which
may have a lower propensity for inducing symptoms.1
SINAM is seen in 2-3 out of 100,000 patients taking
statins.1 SINAM is characterized by progressive
proximal muscle weakness, significantly elevated
CPK levels (1000-10 000 units/L), abnormal EMG
and muscle biopsy, and presence of a marker of
autoimmune injury called anti-HMGCoA ab, which
has 94.4% sensitivity and 99.3% specificity.2 CPK
normalizes and symptoms of SINAM improve after
administration of immunosuppressants. Symptoms
fail to resolve by just stopping the statin alone in
most cases.2 Some patients with mild weakness
from SINAM will improve with the cessation of statin
alone.2
Diagnosis of SINAM can be confirmed with serology
for the HMGCoA ab, muscle biopsy (showing
scattered necrotic muscle fibers undergoing
myophagocytosis and scant inflammation) and EMG
(showing increased spontaneous activity, myopathic
motor unit action potentials (MUAPs) with low
amplitude, short duration, polyphasia and early
recruitment).3
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Typically, the first line treatment for SINAM is
a combination of a steroid with a secondary
immunosuppressive agent such as methotrexate,
azathioprine, or mycophenolate.4 Intravenous
immunoglobulin (IVIG) is highly efficacious as a
monotherapy and in cases of refractory SINAM.
Our patient was treated for over 2 years with
methotrexate and remained stable. Long term
immunosuppression is suggested in SINAM
patients as regenerating muscle fibers in positive
anti-HMGCR patients have shown upregulation
in HMGCR expression, which can prolong the
autoimmune response.6
Autoimmune myopathies can occur when
genetically susceptible individuals are exposed to
specific environmental triggers and it was shown
that those with HLA-DR11 are predisposed towards
SINAM.7 It has been shown that around 50% of
autoimmune diseases have been precipitated by
unknown factors.6 Prior to disease onset, studies
have shown upwards of 80% of patients who
develop autoimmune symptoms experienced
emotional stress.8 In our patient’s case, it is
important to consider that the stress from the motor
vehicle accident was the triggering environmental
factor for SINAM, but cannot be definitively proven.
The patient’s HLA subtype was not tested for, but
would also be an important factor to consider
testing for in patients with SINAM. Although SINAM
is a rare complication of statin therapy, it should be
considered in patients presenting with proximal
muscle weakness, elevated CK, and long term statin
use.
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ABBREVIATIONS
CK - creatinine kinase
CPK - creatinine phosphokinase
HMGCR - 3-Hydroxy-3-Methylglutaryl-CoA
Reductase
STIR - Short TI inversion Recovery
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